Role of daratumumab in the frontline management of multiple myeloma: a narrative review-Reference-Cited by-同舟云学术

Role of daratumumab in the frontline management of multiple myeloma: a narrative review

Published:2023-08-18 Issue:10 Volume:16 Page:743-760
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Yadav Sanjeev¹^ORCID,Gundeti Sadashivudu²,Bhave Abhay³,Deb Uttiya⁴^ORCID,Dixit Jitendra⁴,Mishra Kundan⁵^ORCID

Affiliation:

1. Department of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

2. Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, India

3. Department of Hematology, Lilavati Hospital and Research Centre, Mumbai, India

4. Medical Affairs, Johnson and Johnson Private Limited, Mumbai, India

5. Department of Hematology, Command Hospital, Lucknow, India

Funder

funded by Johnson & Johnson Pvt Ltd, India

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2023.2246651

Reference107 articles.

1. World Health Organization. Global cancer observatory: cancer today. Lyon France: International Agency For Research On Cancer [cited 2023 Jan 3]. Available from: https://gco.iarc.fr/today

2. Prevalence of multiple myeloma and its complication in a tertiary medical college at Calicut district, India

3. Priapism as the Presenting Manifestation of Multiple Myeloma

4. Macroglossia and amyloidosis

5. American Cancer Society. Key statistics about multiple myeloma. [cited 2023 Jan 3]. Available from: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. The role of antibody glycosylation in autoimmune and alloimmune kidney diseases;Nature Reviews Nephrology;2024-07-03

3. Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma;Therapeutic Advances in Medical Oncology;2024-01